First-Quarter 2023 Revenues of $18.3 Billion
Expected Decline in Comirnaty(1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues
First-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $7.1 Billion
Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 5% Operationally
First-Quarter 2023 Reported Diluted EPS(2) of $0.97, a Year-Over-Year Decline of 29%, and Adjusted Diluted EPS(3) of $1.23, a Year-Over-Year Decline of 24%
Pfizer Reaffirms Full-Year 2023 Financial Guidance(4)
Pfizer Continued to Make Significant Progress Toward an Unprecedented Number of Anticipated New Product and Indication Launches; Milestones Include FDA Approvals for Zavzpret, Cibinqo for Adolescents and Prevnar 20 in Pediatric Patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.